# COSINR: HCP commentary report

> 235 verified statements (181 from clinicians verified by NPI or staff page) from 21 commentary sources · 12 findings · updated Oct 30, 2026

## Report

- Trial: A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)
- NCT ID: NCT03223155
- Registry: https://clinicaltrials.gov/study/NCT03223155
- Sponsor: University of Chicago
- Phase: Phase 1
- Status: Active, not recruiting
- Drugs tested: nivolumab plus ipilimumab plus stereotactic body radiotherapy
- Indication: stage IV non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: bb6847f2c5df1439c53118ac716f766994a58469289db6d1759b1065d9f00425

## Counts

- HCP commentary sources screened: 28
- Sources cited by verified statements: 23
- Verified statements: 235
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 181
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 41
- Voices cited: 39
- Cited voices identity-verified: 37
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

COSINR examines the safety of giving stereotactic body radiotherapy concurrently or sequentially with nivolumab–ipilimumab in stage IV NSCLC. Commentary comes from X posts and threaded exchanges. Debate centers on whether radiation adds systemic benefit, when concurrent SBRT–immunotherapy is appropriate, and the contested clinical relevance of proposed dormancy escape. The sources place COSINR presentation findings at ASTRO 2020 and COSINR trial results at WCLC2023.

## Open Medical Affairs question

What evidence would isolate SBRT's incremental benefit and validate actionable dose, timing or biomarker choices without overstating systemic harm?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Radiation's added systemic contribution remains an explicit question despite strong enthusiasm
- F2. Favorable concurrent-treatment reports use distinct endpoints and incomplete presentation summaries
- F3. Avoiding systemic-treatment delay is a conditional argument, not an unconditional preference for concurrency
- F4. Misreading COSINR as oligometastatic consolidation changes the clinical question
- F5. The AREG interpretation concerns possible dormancy escape, not a demonstrated increase in metastatic spread
- F6. Human validation, causal discrimination and real-world importance remain contested
- F7. Partial-coverage concerns include a negative association and an explicit self-correction
- F8. More ablative radiation has a systemic-treatment trade-off, not just a local-control rationale
- F9. Evidence-generation concerns combine statistical power, accrual competition and disputed modality bias
- F10. The rationale extends beyond abscopal effects, while timing and measurement remain unsettled
- F11. YTHDF2 adds a resistance hypothesis, not a clinically validated intervention or sequencing biomarker
- F12. Patient-facing communication is a consequential controversy alongside the science

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 9 | 4 | 7 | recorded | 3 |
| F2 | 8 | 8 | 7 | 5 | recorded | 3 |
| F3 | 9 | 8 | 1 | 5 | recorded | 5 |
| F4 | 12 | 9 | 3 | 6 | recorded | 3 |
| F5 | 16 | 16 | 3 | 4 | recorded | 3 |
| F6 | 21 | 24 | 2 | 8 | recorded | 3 |
| F7 | 14 | 11 | 4 | 3 | recorded | 4 |
| F8 | 8 | 8 | 3 | 5 | recorded | 3 |
| F9 | 15 | 16 | 2 | 7 | recorded | 3 |
| F10 | 17 | 15 | 2 | 8 | recorded | 3 |
| F11 | 8 | 7 | 2 | 1 | none recorded | 3 |
| F12 | 16 | 15 | 3 | 10 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 2 | 0 | 0 | 1 | 9 | 0 | 3 posts and articles, 1 registry | yes |
| F2 | 6 | 0 | 0 | 0 | 2 | 10 | 1 | 7 posts and articles | yes |
| F3 | 6 | 1 | 1 | 1 | 0 | 9 | 1 | 1 post or article | yes |
| F4 | 5 | 2 | 0 | 0 | 5 | 12 | 1 | 2 posts and articles, 1 registry | yes |
| F5 | 15 | 1 | 0 | 0 | 0 | 16 | 0 | 3 posts and articles | yes |
| F6 | 12 | 7 | 0 | 0 | 2 | 24 | 0 | 2 posts and articles | yes |
| F7 | 6 | 4 | 0 | 0 | 4 | 14 | 0 | 4 posts and articles | yes |
| F8 | 5 | 2 | 0 | 1 | 0 | 8 | 2 | 3 posts and articles | yes |
| F9 | 9 | 2 | 1 | 2 | 1 | 15 | 1 | 2 posts and articles | yes |
| F10 | 9 | 6 | 0 | 0 | 2 | 17 | 0 | 2 posts and articles | yes |
| F11 | 5 | 0 | 0 | 0 | 3 | 8 | 0 | 1 post or article, 1 publication | yes |
| F12 | 11 | 2 | 1 | 0 | 2 | 17 | 1 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Number of serious adverse events: no finding draws on it directly
- Secondary endpoints: F1 (1 shared claims), F2 (2 shared claims), F5 (1 shared claims), F6 (1 shared claims), F11 (1 shared claims), F12 (1 shared claims)
- Population and setting: F4 (7 shared claims), F7 (1 shared claims)
- The comparison: F2 (3 shared claims), F3 (9 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (4 shared claims), F3 (3 shared claims), F8 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F9 (15 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Radiation's added systemic contribution remains an explicit question despite strong enthusiasm

An X-thread post asks how radiation’s contribution in COSINR can be separated from a tumor’s responsiveness to immunotherapy.

Source: X thread, 2025-11-20.

### F6. Human validation, causal discrimination and real-world importance remain contested

An X poster asks how the AREG hypothesis discussed in connection with COSINR could be tested in humans and distinguished from ordinary metastatic progression.

Source: X thread, 2025-10-22.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 235 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 23 | Counts free |
| Speaker attribution for cited voices | 39 | Paid |

## Trial aspects

13 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of serious adverse events | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 6 | 6 |
| Population and setting | discussed | 8 | 2 |
| The comparison | discussed | 14 | 8 |
| Safety and tolerability | discussed | 8 | 6 |
| Design and conduct | discussed | 22 | 6 |
| Clinical enthusiasm, chemotherapy-free appeal and radiation's incremental value | discussed | 13 | 7 |
| Dose, target selection and continuity of systemic treatment | discussed | 23 | 6 |
| Human timing evidence, tissue biology and translational measurements | discussed | 11 | 5 |
| AREG, dormancy escape and the meaning of post-SBRT progression | discussed | 29 | 3 |
| Causal validation, failure-pattern analysis and clinical meaningfulness | discussed | 56 | 1 |
| Partial SBRT, treated-lesion control and complete consolidation | discussed | 22 | 5 |
| YTHDF2-associated dendritic-cell resistance and experimental targeting | discussed | 6 | 1 |
| Local-therapy analogues, scientific framing and patient counseling | discussed | 31 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 28 | 21 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2018-02-13 to 2025-11-28
- Cited window: 2018-06-14 to 2025-11-28
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)
- Registry: NCT03223155 (https://clinicaltrials.gov/study/NCT03223155)
- Study IDs: IRB17-0547
- Sponsor: University of Chicago
- Design: Phase 1 · interventional, randomized, parallel, phase1
- Status: Active, not recruiting
- Enrollment: 78 (actual)
- Start: 2017-09-07 (actual)
- Primary completion: 2026-12 (estimated)
- Primary endpoint: Number of serious adverse events (Up to 4 years)
- Intervention: Nivolumab (drug)
- Intervention: Ipilimumab (drug)
- Intervention: Stereotactic body radiation therapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 118 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.
- Some discussion passages and treatment-development suggestions were not fully assessed, and unnamed references or alternative transcriptions may be missing. Absence of a view here does not establish that no such view exists or that every proposed approach has been characterized.
- A complete protocol and the complete main clinical-results publication are not available. Presentation summaries and participant recalculations should not substitute for a full endpoint-level assessment.
- The registry condition labels describe small cell lung cancer, while the trial title, methods statement and commentary specify stage IV NSCLC. The report follows the latter clinical setting.
- Clinical associations involving AREG or YTHDF2 do not establish causation, predictive utility, a sequencing rule or benefit from a targeted intervention.
- Some numerical presentation summaries omit denominators, timepoints or group assignments; values from different presentations are not interchangeable.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A speaker's favorable appraisal accompanies a post sharing COSINR results. Another speaker's AREG explanations concern the group's own research, including COSINR analyses. These should not be read as independent external reception.
- A speaker's involvement is described by the source as working for The University, the trial's sponsor; this description is not independent verification of employment or a reason to weight the view as external consensus.
- Surgical, bladder-RT and other-trial examples are used only where they qualify the connected treatment or evidence question; they are not COSINR treatment arms or outcomes. The pulmonary-vessel-ligation comparison is a reported study observation posted in 2019 about lung-cancer resection.
- Concerns about patient fear, specialty bias and media effects are attributed opinions or anticipated risks, not independently measured findings.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition, corrected 2026-10-30
  - Correction 2026-10-30: Corrected to match the delivered report: the sample findings; the report description.

Last checked for new commentary 2026-10-30. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (235 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (37 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/cosinr-nct03223155
- Agents: POST https://www.erudio.com/api/orders with {"report": "cosinr-nct03223155", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=cosinr-03223155

## Cite

Erudio Health. COSINR (NCT03223155): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/cosinr-nct03223155

## Machine access

- JSON: https://www.erudio.com/reports/cosinr-nct03223155.json
- Markdown: https://www.erudio.com/reports/cosinr-nct03223155.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "cosinr-03223155"}`